Trial Profile
The prospective, open-label, multicentre, non-comparative, observational post-marketing surveillance study evaluating efficacy and tolerability of TRIoptal (OXcarbazepine) in children and adolescents with newly diagnosed partial seizures or generalized tonic-clonic seizures as monotherapy in routine clinical practice
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2016
Price :
$35
*
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Therapeutic Use
- Acronyms TRIOX
- Sponsors Novartis
- 09 Dec 2010 New trial record